Payment overview · 2025
General Payments
$276.81
15 reported records · 6 companies
Healthcare provider profile · identity verified
Manish Shroff, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · BIG SPRING, TX · NPI 1447270095
Verified facts
What the public records show
CMS Open Payments records show Manish Shroff, M.D. received $276.81 in general payments during 2025 across 15 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 48.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $135.38 | 48.9% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $60.88 | 22.0% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $24.78 | 8.9% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.97 | 8.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.42 | 5.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.38 | 5.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $276.81 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $135.38 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $60.88 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $16.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 103 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 157 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
103 | 29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
157 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1357 | 286 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1216 | 211 |
| Losartan Potassium | Losartan Potassium | 759 | 180 |
| Amlodipine Besylate | Amlodipine Besylate | 708 | 148 |
| Metoprolol Tartrate | Metoprolol Tartrate | 678 | 167 |
| Lisinopril | Lisinopril | 660 | 145 |
| Gabapentin | Gabapentin | 627 | 149 |
| Pantoprazole Sodium | Pantoprazole Sodium | 607 | 192 |
| Potassium Chloride | Potassium Chloride | 590 | 119 |
| Januvia | Sitagliptin Phosphate | 480 | 70 |
| Tramadol Hcl | Tramadol Hcl | 475 | 109 |
| Metformin Hcl | Metformin Hcl | 470 | 118 |
| Hydrochlorothiazide | Hydrochlorothiazide | 459 | 108 |
| Clopidogrel | Clopidogrel Bisulfate | 432 | 100 |
| Furosemide | Furosemide | 400 | 83 |
| Donepezil Hcl | Donepezil Hcl | 395 | 56 |
| Eliquis | Apixaban | 382 | 72 |
| Spironolactone | Spironolactone | 377 | 105 |
| Celecoxib | Celecoxib | 362 | 112 |
| Azithromycin | Azithromycin | 319 | 218 |
| Carvedilol | Carvedilol | 313 | 70 |
| Duloxetine Hcl | Duloxetine Hcl | 307 | 52 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 306 | 52 |
| Prednisone | Prednisone | 292 | 148 |
| Escitalopram Oxalate | Escitalopram Oxalate | 285 | 45 |
| Hydralazine Hcl | Hydralazine Hcl | 280 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 261 | 44 |
| Famotidine | Famotidine | 245 | 100 |
| Zolpidem Tartrate | Zolpidem Tartrate | 245 | 39 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 243 | 172 |
| Tamsulosin Hcl | Tamsulosin Hcl | 242 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 227 | 80 |
| Buspirone Hcl | Buspirone Hcl | 216 | 40 |
| Sertraline Hcl | Sertraline Hcl | 211 | 38 |
| Alprazolam | Alprazolam | 193 | 39 |
| Methylprednisolone | Methylprednisolone | 192 | 149 |
| Fenofibrate | Fenofibrate Nanocrystallized | 182 | 37 |
| Glipizide | Glipizide | 181 | 56 |
| Methocarbamol | Methocarbamol | 173 | 52 |
| Memantine Hcl | Memantine Hcl | 170 | 28 |
| Simvastatin | Simvastatin | 170 | 36 |
| Bumetanide | Bumetanide | 169 | 54 |
| Jardiance | Empagliflozin | 157 | 36 |
| Mounjaro | Tirzepatide | 157 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 151 | 41 |
| Meloxicam | Meloxicam | 150 | 39 |
| Omeprazole | Omeprazole | 142 | 34 |
| Trazodone Hcl | Trazodone Hcl | 141 | 32 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 139 | 34 |
| Ropinirole Hcl | Ropinirole Hcl | 138 | 22 |
| Ozempic | Semaglutide | 133 | 21 |
| Levetiracetam | Levetiracetam | 129 | 20 |
| Pregabalin | Pregabalin | 123 | 29 |
| Mirtazapine | Mirtazapine | 122 | 24 |
| Allopurinol | Allopurinol | 121 | 29 |
| Amiodarone Hcl | Amiodarone Hcl | 116 | 45 |
| Montelukast Sodium | Montelukast Sodium | 115 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 115 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 114 | 12 |
| Divalproex Sodium | Divalproex Sodium | 103 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 103 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 100 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 99 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 95 | 75 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 95 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 94 | suppressed |
| Glimepiride | Glimepiride | 91 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 91 | 55 |
| Entresto | Sacubitril/Valsartan | 85 | 19 |
| Ibuprofen | Ibuprofen | 85 | 34 |
| Clonazepam | Clonazepam | 82 | 11 |
| Mupirocin | Mupirocin | 81 | 49 |
| Clonidine Hcl | Clonidine Hcl | 79 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 20 |
| Meclizine Hcl | Meclizine Hcl | 73 | 22 |
| Sucralfate | Sucralfate | 72 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 71 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 16 |
| Clindamycin Hcl | Clindamycin Hcl | 67 | 51 |
| Cefdinir | Cefdinir | 63 | 52 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | suppressed |
| Xarelto | Rivaroxaban | 63 | 21 |
| Fluconazole | Fluconazole | 62 | 34 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 48 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 59 | suppressed |
| Metronidazole | Metronidazole | 57 | 54 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 57 | 45 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 54 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 25 |
| Ezetimibe | Ezetimibe | 53 | 13 |
| Novolog Flexpen | Insulin Aspart | 53 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 52 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 52 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 52 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 52 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 51 | 11 |
| Baclofen | Baclofen | 51 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 50 | 16 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 49 | 35 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 49 | 17 |
| Finasteride | Finasteride | 47 | 11 |
| Aripiprazole | Aripiprazole | 46 | suppressed |
| Cephalexin | Cephalexin | 46 | 35 |
| Nitroglycerin | Nitroglycerin | 45 | 37 |
| Nystatin | Nystatin | 45 | 29 |
| Methimazole | Methimazole | 44 | suppressed |
| Valsartan | Valsartan | 44 | 12 |
| Hydrocortisone | Hydrocortisone | 43 | 22 |
| Risperidone | Risperidone | 43 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 42 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 42 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 39 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 13 |
| Megestrol Acetate | Megestrol Acetate | 38 | 15 |
| Memantine Hcl Er | Memantine Hcl | 38 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 38 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 38 | suppressed |
| Tradjenta | Linagliptin | 36 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 35 | 12 |
| Dexamethasone | Dexamethasone | 33 | 30 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 33 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Amantadine | Amantadine Hcl | 32 | suppressed |
| Levofloxacin | Levofloxacin | 32 | 31 |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 32 | suppressed |
| Topiramate | Topiramate | 32 | 12 |
| Lorazepam | Lorazepam | 31 | 11 |
| Ofloxacin | Ofloxacin | 31 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Klor-Con 8 | Potassium Chloride | 30 | 11 |
| Oxcarbazepine | Oxcarbazepine | 30 | suppressed |
| Timolol Maleate | Timolol Maleate | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 20 |
| Olanzapine | Olanzapine | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 25 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 16 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 22 | suppressed |
| Constulose | Lactulose | 22 | 14 |
| Folic Acid | Folic Acid | 22 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 19 | 19 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Lactulose | Lactulose | 19 | 15 |
| Latanoprost | Latanoprost | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Hydroxyurea | Hydroxyurea | 15 | suppressed |
| Acetazolamide | Acetazolamide | 14 | suppressed |
| Calcium Acetate | Calcium Acetate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Novolin R | Insulin Regular, Human | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | 12 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | 11 |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $276.81 · 15 records | Boehringer Ingelheim Pharmaceuticals, Inc. | FARXIGA, GVOKE HYPOPEN, JARDIANCE, Ohtuvayre, VERQUVO, XIFAXAN | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error